SCHEMBL3501272

SCHEMBL3501272

Cc1ccc(Br)c2nsnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
PKM P14618 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 4/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 3/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 1/20 0.38
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
HSP90AA1 P07900 1/20 0.36
THRB P10828 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246997 0.85 MAPT (0.44) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL178958 0.85 MAPT (0.54) MAPTMEN1KMT2APKMSMN1; SMN2
SCHEMBL20428806 0.76 MAPT (0.40) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL13780495 0.76 MAPT (0.47) MAPTMEN1KMT2APKMSMN1; SMN2
SCHEMBL13845365 0.73 KMT2A (0.35) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL10382705 0.73 MAPT (0.38) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL12943441 0.73 MAPT (0.44) MAPTMEN1KMT2APKMSMN1; SMN2
SCHEMBL19028000 0.73 MAPT (0.53) MAPTMEN1KMT2APKMSMN1; SMN2
SCHEMBL13145923 0.73 MAPT (0.44) MAPTMEN1KMT2APKMSMN1; SMN2
SCHEMBL12826057 0.72 KDM4E (0.36) MAPTKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 US disclosed
EP-3873605-B1 COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN GILEAD SCIENCES INC (US) 2024-10-23 EP disclosed
CN-112969504-B Compounds for inhibiting alpha 4 beta 7 integrin 吉利德科学公司 2024-04-09 CN disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
US-11629134-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2023-04-18 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20220152014-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. (US) 2022-05-19 US disclosed
US-11179383-B2 Compounds for inhibition of α4β7 integrin GILEAD SCIENCES, INC. (US) 2021-11-23 US disclosed
US-20130019949-A1 COMPOUNDS FOR ORGANIC THIN-FILM SOLAR CELLS AND ORGANIC THIN-FILM SOLAR CELLS Lin, Hao-Wu 2013-01-24 US disclosed
US-20120312374-A1 CONJUGATED FLUORENE POLYMER, PREPARING METHOD THEREOF AND SOLAR CELL DEVICE OCEAN'S KING LIGHTING SCIENCE & TECHNOLOGY CO., LTD. (CN) 2012-12-13 US disclosed
US-20120214255-A1 METHODS AND COMPOSITIONS FOR ASSAYING A SAMPLE FOR AN AGGREGANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-23 US disclosed
US-8110673-B2 Aggregation sensor and solutions and kits comprising the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-07 US disclosed
WO-2011075607-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-06-23 WO disclosed
US-20100255477-A1 METHODS AND COMPOSITIONS FOR ASSAYING A SAMPLE FOR AN AGGREGANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-07 US disclosed
US-20100184601-A1 Method and Means Relating to Multiple Herbicide Resistance in Plants UNIVERSITY OF DURHAM (GB) 2010-07-22 US disclosed
EP-2190290-A2 METHOD AND MEANS RELATING TO MULTIPLE HERBICIDE RESISTANCE IN PLANTS University Of Durham (GB) 2010-06-02 EP disclosed
WO-2010022058-A1 ACTIVE MATERIALS FOR PHOTOELECTRIC DEVICES AND DEVICES THAT USE THE MATERIALS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-02-25 WO disclosed
WO-2009034396-A2 METHOD AND MEANS RELATING TO MULTIPLE HERBICIDE RESISTANCE IN PLANTS UNIVERSITY OF DURHAM (GB) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 MAPT 4219/4885MEN1 4517/4885KMT2A 1063/4885
US-11629134-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 MAPT 4219/4885MEN1 4517/4885KMT2A 1063/4885
US-11179383-B2 Compounds for inhibition of α4β7 integrin ITGB7, ITGB4, ITGA4 MAPT 3196/4885MEN1 4020/4885KMT2A 3948/4885
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 MAPT 2208/4885MEN1 3166/4885KMT2A 1040/4885
US-20100184601-A1 Method and Means Relating to Multiple Herbicide Resistance in Plants GSTO1, GSTP1, GSR MAPT 3504/4885MEN1 4463/4885KMT2A 1267/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 MAPT 4219/4885MEN1 4517/4885KMT2A 1063/4885
US-20220152014-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 MAPT 3224/4885MEN1 3521/4885KMT2A 4050/4885
US-20130019949-A1 COMPOUNDS FOR ORGANIC THIN-FILM SOLAR CELLS AND ORGANIC THIN-FILM SOLAR CELLS CDH1, FTO, SUN2 MAPT 1180/4885MEN1 422/4885KMT2A 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.